Navigation Links
GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
Date:10/30/2008

otal mortality for AVANDIA compared to other commonly used oral diabetes medicines on the market. The current FDA-approved label for AVANDIA states that the available data are inconclusive on the risk of myocardial ischemia.

Important Safety Information about AVANDIA(R) (rosiglitazone maleate)

Prescription AVANDIA, along with diet and exercise, helps improve blood sugar control in adults with type 2 diabetes. Taking AVANDIA with insulin or nitrates is not recommended.

AVANDIA can cause or worsen heart failure. If you have severe heart failure (very poor pumping ability of the heart) you cannot be started on AVANDIA. AVANDIA is also not recommended if you have heart failure with symptoms (such as shortness of breath or swelling) even if these symptoms are not severe.

AVANDIA may increase your risk of other heart problems that occur when there is reduced blood flow to the heart, such as chest pain (angina) or heart attack (myocardial infarction). This risk appeared higher in patients taking medicines called nitrates or insulin.

If you have chest pain or a feeling of chest pressure, you should seek immediate medical attention, regardless of what diabetes medicines you are taking. If you take AVANDIA tell your doctor right away if you: have swollen legs or ankles, a rapid increase in weight or difficulty breathing, or unusual tiredness; experience changes in vision; become pregnant.

Before taking AVANDIA, review your medical history and tell your doctor if you:

-- Have heart failure or other heart problems, or are on any medicines for

high blood pressure, high cholesterol or heart failure, or for

prevention of heart disease or stroke.

-- Take insulin or nitrate medicines.

-- Have a type of diabetic eye disease called macular edema.

-- Have liver problems or had liver problems while taking REZULIN(R)

(troglitazone).

-- Are pregnant or planning to become preg
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
3. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
4. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
5. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
6. New Data Support Earlier Suggested Guidance for Levels of Cell-Mediated Immunity in Pediatric Liver Transplant Patients
7. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
8. The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
9. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
10. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
11. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... today that it has completed notifying customers of a ... the United States and has confirmed that 51 have ... on October 11, 2011 to address a manufacturing issue ... reports of ventilator malfunctions, failures or injuries related to ...
... a global biopharmaceutical company dedicated to developing life-saving medicines ... ischemic (oxygen deprived) tissues through targeted oxygen and other ... 1b study designed to evaluate the safety of MP4CO ... designed to deliver therapeutic levels of carbon monoxide (CO) ...
Cached Medicine Technology:Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators 2Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease 2Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it ... Bronx campus. The goal is to bring this Torah – dating from 1880 – ... rituals and religious services. , Scroll No. 515, from the town of Taus-Domazlice, ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... supporters will discuss implications of federal health-reform bills at the ... at 9:00 am. Health-policy experts will examine which proposed legislation ... will make sure Americans are not forced to have a ... cradle to grave and that citizens are not forced to ...
... Pa., June 17 The GBS/CIDP Foundation International, ... afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating ... Patricia A. Bryant to the position of Executive ... succeeds Estelle L. Benson, who along with her ...
... (June 17, 2009) Two new studies published by ... demonstrate a need for more vigilant monitoring for seizure ... subtle seizures that are typically unrecognized. These subtle seizures ... damage, death and severe disability. Published in recent ...
... A $4.15 million, four-year National Institutes of Health grant ... Medicine to conduct the first health study of teenage ... Dennis Fortenberry, M.D., M.S., professor of pediatrics in the ... follow 72 males, ages 14-17 years, for three years. ...
... , CiNet Acquires Industry-Leading Training Assets to Help ... Workplace Efficiency , , DALLAS, June 17 ... emerging eLearning company serving customers across the public ... the formal launch of its business operations. ...
... also guards against infection, study shows , WEDNESDAY, June ... development of emphysema also defends the lungs against bacterial ... thought that the only thing macrophage elastase, matrix metalloproteinase-12 ... the tissue destruction seen in emphysema patients. , "But ...
Cached Medicine News:Health News:GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 3Health News:Cellular telephones to expand knowledge of health behaviors and microorganisms in adolescent males 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 3Health News:Lung Enzyme Both Friend and Foe 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: